Smith & Nephew plc (LON: SN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 8.95B |
| Revenue (ttm) | 4.37B |
| Net Income (ttm) | 207.01M |
| Shares Out | 875.10M |
| EPS (ttm) | 0.24 |
| PE Ratio | 42.65 |
| Forward PE | 12.27 |
| Dividend | 0.38 (3.66%) |
| Ex-Dividend Date | Mar 28, 2024 |
| Volume | 2,425,623 |
| Open | 1,023.50 |
| Previous Close | 1,025.00 |
| Day's Range | 1,019.50 - 1,027.50 |
| 52-Week Range | 887.00 - 1,284.00 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | 13.98 (-98.63%) |
| Earnings Date | Aug 1, 2024 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other... [Read more]
Financial Performance
In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.
Financial numbers in USD Financial StatementsNews
MIDAS SHARE TIPS: Why it soon won't be hip to give the cold shoulder to Smith & Nephew
S&N is far from perfect - but, overlooking the issues, the company is cheap and worth buying for short-term upside.
Smith & Nephew rocked as 43% of investors rebel over fat cat pay
In what amounted to a bloody nose for the FTSE 100 firm, 43% of investors voted against raising Deepak Nath's maximum earnings to £9.4m.
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Nearly half of Smith & Nephew investors revolt against chief executive pay increase
Medical device manufacturer’s policy ultimately passed, making maximum payout for Deepak Nath $11.8m Nils Pratley: The boardroom pay game has changed for ever Smith & Nephew had a shareholder revolt o...
At 3-0 to the Brilos, the boardroom pay game has changed forever | Nils Pratley
As Smith & Nephew is ‘British in listing only’ investors have been persuaded the CEO should be remunerated accordingly Our performance has been so bad that we must pay our executives more. If this cor...
BUSINESS CLOSE: GSK raises guidance; Next exceeds forecasts; Aston Martin losses nearly double
Among the companies with reports and trading updates today are Next, GSK, Aston Martin Lagonda, Haleon, CVS Group, Smith & Nephew and Computacenter.
UK's Smith+Nephew retains annual forecasts despite Q1 revenue miss
British medical equipment maker Smith+Nephew retained its annual revenue and profit forecasts on Wednesday, despite marginally missing market expectations for first-quarter revenue due to a softness i...
Three Quick Facts: Computacenter, Next, Smith & Nephew
Tony Cross picks three things to know about the markets, featuring Computacenter, Next, Smith & Nephew
Smith & Nephew investors urged to oppose ‘excessive’ pay rise for boss
FTSE 100 group wants to raise US-based Deepak Nath’s pay by almost 30% to a maximum of $11.8mn
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, anno...
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE)...
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centr...
Smith & Nephew goes ex dividend Monday
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial ar...
British MedTech Firm Smith & Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder Skepticism
British multinational medical equipment manufacturing company Smith & Nephew Plc (NYSE: SNN) is set to revamp its executive pay structure, signaling a departure from the U.K. market norms, as the com...
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew plc 2023 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Smith & Nephew plc in conjunction with their 2023 Q4 earnings call.
Smith & Nephew reports Q4 results
Smith & Nephew eyes stronger margins as orthopaedics demand drives profits to £764m
Smith & Nephew expects profit margins to continue to improve this year after beating market expectations for 2023 earnings.
Three Quick Facts: Smith & Nephew, Unite, abrdn
Tony Cross picks three things to know about the markets, featuring Smith & Nephew, Unite, abrdn
A quiet conspiracy is afoot to give FTSE 100 executives a pay rise | Nils Pratley
As the London market’s woes are blamed on remuneration, a new US benchmark is emerging It seems the UK financial and corporate establishment is agreed. The London stock market is in a funk, with too m...
Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use wit...
Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting
Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* fo...
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant alongside the REGENET...
Australia's approach to musculoskeletal injury care and reimbursement demands rethink: Report
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and ...